定义非酒精性脂肪性肝炎治疗试验终点的改善:肝脏论坛的建议
肝脏论坛多利益相关方组织从监管科学角度出发,综述可用于反映非酒精性脂肪性肝炎(NASH)治疗应答的组织学、血液和影像药效学生物标志物数据,并提出在2期和3期试验及上市后监测中应考虑的测量指标建议。
要点
- 肝脏论坛建议在2期和3期NASH试验及上市后监测中考虑特定的组织学、血液和影像药效学生物标志物测量。
- NASH临床试验设计面临困难,因疾病长期症状轻微且缺乏可靠预测肝脏相关疾病和死亡的癌前试验终点。
- 肝脏论坛既往工作聚焦于临床试验中疾病定义和基线参数的建议,以评估疾病状态并预防进展。
核心结论
- 综述现有临床数据以识别与肝脏组织学平行变化且可能反映肝硬化及其并发症风险有临床意义降低的参数,并据此提出2期和3期试验及上市后监测中应考虑的测量建议。
研究设计与样本
- 肝脏论坛是一个由学术、工业和监管专家组成的多利益相关方组织,从监管科学角度识别障碍、优先研究并寻找加速NASH治疗开发的解决方案。
主要发现
- 发达国家1%-2%的人群有发生NASH肝硬化及其并发症的风险。
- NASH临床治疗试验设计受限于疾病长期症状轻微且通常先于失代偿性肝硬化发生,以及关于最佳癌前试验终点可靠反映后续肝脏相关疾病和死亡降低的不确定性。
关键数值与推荐
- 建议在2期和3期试验以及上市后监测试验中考虑特定的组织学、血液和影像药效学生物标志物测量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Identifying effective therapies for nonalcoholic steatohepatitis (NASH) with fibrosis is a pressing challenge, with 1%-2% of the population in developed nations at risk of developing NASH cirrhosis and its complications. The design of NASH clinical therapeutic trials is hampered by the long period of minimally symptomatic disease that typically precedes the development of decompensated cirrhosis and the accompanying uncertainties regarding the best precirrhotic trial endpoints that reliably reflect a subsequent reduction in liver-related morbidity and mortality. The Liver Forum is a multistakeholder organization comprised of academic, industry, and regulatory experts working from a regulatory science perspective to identify barriers, prioritize research, and identify solutions to accelerate therapeutic development for NASH. Past work of The Liver Forum has focused on recommendations for disease definitions and baseline parameters to be implemented in clinical trials that are designed to assess disease status and prevent progression to cirrhosis, liver transplantation, hepatocellular carcinoma, and death. The purpose of this summary is to review currently available clinical data to identify parameters that change in parallel with liver histology and are likely to reflect clinically meaningful reductions in the risk of developing cirrhosis and its complications. We review available data on exploratory histological, blood-based, and imaging pharmacodynamic biomarkers that may reflect meaningful treatment responses and provide recommendations regarding measurements to be considered in phase 2 and 3 trials as well as during postmarketing monitoring trials.
引用
- Cheung A, Neuschwander-Tetri BA, Kleiner DE, et al. Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. Hepatology. 2019. PMID: 31034092. doi:10.1002/hep.30672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。